{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events.","groupId":"OG000","lowerLimit":"4.17","upperLimit":"NA","value":"9.03"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"}],"units":"Participants"}],"description":"PFS is defined as the time from JCAR017 infusion to progressive disease (PD) or death. Kaplan-Meier (KM) methodology will be used to analyze PFS.\n\nPD = Score 4 or 5b on the positron emission tomography 5-point scale (PET 5PS) with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment.\n\nPET 5PS = 1- no uptake above background; 2- uptake ≤ mediastinum; 3- uptake \\> mediastinum but ≤ liver; 4- uptake moderately \\> liver; 5- uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.","id":"OG000","title":"Lisocabtagene Maraleucel (JCAR017)"}],"paramType":"MEDIAN","populationDescription":"All participants with PET positive disease who received at least one infusion of JCAR017","reportingStatus":"POSTED","timeFrame":"From first dose to progressive disease (PD) or death (up to approximately 24 months)","title":"Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}